Hit-to-lead evaluation of a novel class of sphingosine 1-phosphate lyase inhibitors

Add time:09/05/2019    Source:sciencedirect.com

Inhibition of sphingosine-1-phosphate lyase has recently been proposed as a potential treatment option for inflammatory disorders such as multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease. In this report we describe our hit-to-lead evaluation of the isoxazolecarboxamide 6, a high-throughput screening hit (in vitro IC50 = 1.0 μM, cell IC50 = 1.8 μM), as a novel S1P lyase inhibitor. We were able to establish basic structure–activity relationships around 6 and succeeded in obtaining X-ray structural information which enabled structure-based design. With the discovery of 28, enzyme activity was quickly improved to IC50 = 120 nM and cell potency to IC50 = 230 nM. The main liability in the established isoxazolecarboxamide hit series was determined to be metabolic stability. In particular we identified that future lead-optimization efforts to overcome this problem should focus on blocking the N-dealkylation on the secondary amine.

We also recommend Trading Suppliers and Manufacturers of Hit-1 (cas 18508-77-5). Pls Click Website Link as below: cas 18508-77-5 suppliers

Prev:Decoquinate (cas 18507-89-6) induces tissue cyst formation by the RH strain of Toxoplasma gondii
Next:Case reportRecurrent multilocular mandibular giant cell granuloma in neurofibromatosis type 1: Evidence for second hit mutation of NF1 gene in the jaw lesion and treatment with curettage and bone substitute materials)